Search
Cholesteryl chloride
go.drugbank.com/drugs/DB14045ExperimentalCholesteryl chloride, also known as 3-chlorocholest-5-ene, is an organochloride derivative of cholesterol. It is presented as a liquid crystal that forms clockwise liquid crystals.
JNJ-42165279
go.drugbank.com/drugs/DB15173InvestigationalJnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).
LuLym-T
go.drugbank.com/drugs/DB17405ExperimentalLuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
JLK-247
go.drugbank.com/drugs/DB17637ExperimentalJLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.[L46686]
Aniline
go.drugbank.com/drugs/DB06728InvestigationalAniline, phenylamine or aminobenzene is an organic compound with the formula C6H5NH2. Consisting of an amine attached to a benzene ring, aniline is the prototypical aromatic amine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesTasurgratinib
go.drugbank.com/drugs/DB21222InvestigationalTasurgratinib has a monoisotopic molecular weight of 587.27 Da.
Vemtoberant
go.drugbank.com/drugs/DB21607InvestigationalVemtoberant has a monoisotopic molecular weight of 619.2 Da.
Delocamten
go.drugbank.com/drugs/DB21711InvestigationalDelocamten has a monoisotopic molecular weight of 377.16 Da.
Black cohosh
go.drugbank.com/drugs/DB13975ApprovedInvestigationalBlack cohosh (Actaea racemosa or Cimicifuga racemosa), a member of the buttercup family, is a perennial plant which native to North America. Historical names for this plant include snakeroot, black bugbane, rattleweed, macrotys, and rheu...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsAZD2315
go.drugbank.com/drugs/DB06540ExperimentalThe drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase